GSK says FDA extends review period for experimental drug momelotinib

(Reuters) – British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis.

Momelotinib is not currently approved in any market.